Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1128/jcm.33.2.497-500.1995 | A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis |
| https://doi.org/10.1136/annrheumdis-2016-210310 | Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial |
| https://doi.org/10.1128/iai.60.6.2237-2245.1992 | Rat monoclonal antibodies against Aspergillus galactomannan |
| https://doi.org/10.1186/s13023-017-0572-x | Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD) |
| https://doi.org/10.1007/s10549-009-0512-0 | The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial |
| https://doi.org/10.1016/s2213-2600(20)30320-9 | Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial |
| https://doi.org/10.1038/s41589-022-01044-0 | Detection of cell–cell interactions via photocatalytic cell tagging |
| https://doi.org/10.1214/16-aos1515 | Minimax estimation of a functional on a structured high-dimensional model |
| https://doi.org/10.1182/bloodadvances.2020001834 | Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis |
| https://doi.org/10.1080/17512433.2019.1607293 | Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura |
| https://doi.org/10.1111/jth.14679 | Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study |
| https://doi.org/10.1038/s41467-019-12704-6 | A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation |
| https://doi.org/10.1007/s43441-021-00282-z | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
| https://doi.org/10.1111/jth.15892 | Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study |
| https://doi.org/10.1208/s12248-023-00880-9 | Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development |
| https://doi.org/10.1080/19420862.2019.1709322 | VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis |
| https://doi.org/10.1111/cts.13864 | A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐ |
| https://doi.org/10.1021/acs.molpharmaceut.0c01001 | Nanobody–siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells |
| https://doi.org/10.1080/13696998.2023.2194193 | Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal |
| https://doi.org/10.1183/13993003.01461-2024 | A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule |
| https://doi.org/10.1186/s13058-024-01788-8 | Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers |
| https://doi.org/10.1182/bloodadvances.2023011858 | Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile |
| https://doi.org/10.1177/0192623320976094 | BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics |
| https://doi.org/10.1158/2767-9764.crc-23-0434 | Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies |
| https://doi.org/10.1038/s41467-024-51909-2 | XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients |
| https://doi.org/10.1186/s13023-024-03361-0 | Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases |
| https://doi.org/10.1124/jpet.123.001593 | Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice |
| https://doi.org/10.1016/j.jacig.2025.100483 | Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa |
| https://doi.org/10.1080/19420862.2024.2415333 | Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan |
| https://doi.org/10.1212/wnl.98.18_supplement.2594 | Evaluating the Effect of BTK Inhibitor Tolebrutinib in Human Tri-culture (P1-1.Virtual) |
| https://doi.org/10.1172/jci116554 | Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. |
| https://doi.org/10.1021/jm00084a002 | A novel class of calcium-entry blockers: the 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines |
| https://doi.org/10.1021/jm00062a015 | Novel heterocyclic analogs of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines |
| https://doi.org/10.1016/j.clpt.2004.10.016 | Clinical assessment of drug-induced QT prolongation in association with heart rate changes |
| https://doi.org/10.1097/00005344-199510000-00010 | Effects of a New Amiodarone-Like Agent, SR 33589, in Comparison to Amiodarone, D,L-Sotalol, and Lignocaine, on Ischemia-Induced Ventricular Arrhythmias in Anesthetized Pigs |
| https://doi.org/10.1309/h86km785q9kbwpw5 | Assessment of the Cost of Fine-Needle Aspiration Cytology as a Diagnostic Tool in Patients With Thyroid Nodules |
| https://doi.org/10.1371/journal.pone.0132404 | Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study |
| https://doi.org/10.1007/s11523-015-0402-9 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy |
| https://doi.org/10.1186/s13023-019-1240-0 | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
| https://doi.org/10.3111/13696998.2010.502854 | Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium |
| https://doi.org/10.3390/ijms21175992 | The Anti-ADAMTS-5 Nanobody® M6495 Protects Cartilage Degradation Ex Vivo |
| https://doi.org/10.1021/ci1000218 | pharmACOphore: Multiple Flexible Ligand Alignment Based on Ant Colony Optimization |
| https://doi.org/10.1016/j.jgo.2017.07.010 | Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial |
| https://doi.org/10.1182/blood.2021013563 | First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results |
| https://doi.org/10.1182/bloodadvances.2020004085 | Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B |
| https://doi.org/10.3389/fimmu.2019.02009 | A Computational Pipeline for the Diagnosis of CVID Patients |
| https://doi.org/10.1002/jcph.1991 | Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| https://doi.org/10.3389/fphar.2022.1029236 | Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs |
| https://doi.org/10.1186/s12934-023-02132-z | Optimizing expression of Nanobody® molecules in Pichia pastoris through co-expression of auxiliary proteins under methanol and methanol-free conditions |
| https://doi.org/10.1097/prs.0b013e318208d371 | Subject Global Evaluation and Subject Satisfaction Using Injectable Poly-l-Lactic Acid versus Human Collagen for the Correction of Nasolabial Fold Wrinkles |
| https://doi.org/10.1039/c7cp02549a | Single-component supported lipid bilayers probed using broadband nonlinear optics |
| https://doi.org/10.3390/s22155581 | Generic Chemometric Models for Metabolite Concentration Prediction Based on Raman Spectra |
| https://doi.org/10.1038/s41422-022-00755-2 | Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation |
| https://doi.org/10.4155/bio-2023-0135 | 2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach) |
| https://doi.org/10.1371/journal.pone.0293503 | Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe |
| https://doi.org/10.1080/17576180.2024.2376949 | Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum |
| https://doi.org/10.1080/09546634.2022.2038361 | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| https://doi.org/10.1002/cpt.1121 | Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? |
| https://doi.org/10.3390/healthcare10081594 | Towards Better Pharmaceutical Provision in Europe—Who Decides the Future? |
| https://doi.org/10.1080/17576180.2024.2340961 | 2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies) |
| https://doi.org/10.1177/26330040231188979 | The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies |
| https://doi.org/10.55563/clinexprheumatol/fhrx3q | Phenotypic spectrum of inclusion body myositis |
| https://doi.org/10.1080/17576180.2024.2376950 | The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays |
| https://doi.org/10.1182/blood-2022-169072 | High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies |
| https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6816 | Targeting of TSLP and IL-13 by the Novel NANOBODY ® Molecule SAR443765 Reduces FeNO in Asthma Following Single Dose Exposure |
| https://doi.org/10.1093/eurpub/ckaa166.1427 | Use of Hexyon/Hexacima/Hexaxim in preterm infants in Europe |
| https://doi.org/10.1016/j.yrtph.2025.105793 | Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider |
| https://doi.org/10.1208/s12248-025-01122-w | Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCR |
| https://doi.org/10.1158/1535-7163.mct-24-1049 | Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors |
| https://doi.org/10.1177/00236772241302537 | The advisory body on animal ethics of a global pharmaceutical company: A global organization to address ethical and societal concerns about animal use |
| https://doi.org/10.1002/jcph.70018 | In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor |
| https://doi.org/10.1016/0014-2999(95)00130-d | SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs |
| https://doi.org/10.1097/00005344-199509000-00016 | SR 33589, a New Amiodarone-Like Agent |
| https://doi.org/10.1111/j.1476-5381.1995.tb16397.x | Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart |
| https://doi.org/10.1300/j094v04n03_05 | A Randomized Placebo-Controlled Trial of Sustained-Release Amitriptyline in Primary Fibromyalgia |
| https://doi.org/10.1007/s12325-012-0025-9 | Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010–2011 influenza season |
| https://doi.org/10.1007/s13300-020-00866-2 | Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study |
| https://doi.org/10.3389/fimmu.2023.1137069 | Large-scale antibody immune response mapping of splenic B cells and bone marrow plasma cells in a transgenic mouse model |
| https://doi.org/10.1200/jco.2017.35.4_suppl.592 | Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial. |
| https://doi.org/10.1007/s13300-019-00749-1 | Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study |
| https://doi.org/10.1016/j.jim.2020.112896 | An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics |
| https://doi.org/10.1007/s10928-023-09849-9 | Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules |
| https://doi.org/10.1038/s41467-019-13379-9 | Author Correction: A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation |
| https://doi.org/10.1002/cpdd.1264 | Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants |
| https://doi.org/10.1136/bmjopen-2023-081835 | Patient preferences in genetic newborn screening for rare diseases: study protocol |
| https://doi.org/10.1097/00005344-199502000-00010 | SR 33589, a New Amiodarone-like Antiarrhythmic Agent |
| https://doi.org/10.1016/0006-2952(86)90379-5 | Amiodarone induced modifications of the phospholipid physical state |
| https://doi.org/10.1016/0014-2999(94)90394-8 | Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro |
| https://doi.org/10.1016/0966-7822(93)90001-x | Some aspects of the crosslinking of gelatin by dextran dialdehydes |
| https://doi.org/10.1016/s0022-3565(25)22957-3 | SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. |
| https://doi.org/10.1016/s0040-4039(00)60102-8 | Metallation of 2-phenylindolizine |
| https://doi.org/10.1016/0223-5234(94)90191-0 | 1-[[4-(Aminoalkoxy)phenyl]sulfonyl]indolizines: a novel class of calcium entry blockers. Relationships between chemical structure, stereoelectronic properties and anticalcic activity |
| https://doi.org/10.1039/c7nr07393c | Carbon nanotubes as nanovectors for intracellular delivery of laronidase in Mucopolysaccharidosis type I |
| https://doi.org/10.1200/jco.2014.32.3_suppl.545 | Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65. |
| https://doi.org/10.1212/wnl.96.15_supplement.4195 | Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients (4195) |
| https://doi.org/10.1097/01.hs9.0000560864.06450.a4 | PF645 EXPOSURE‐RESPONSE ANALYSIS & DISEASE MODELING FOR SELECTION OF OPTIMAL DOSING REGIMEN OF ISATUXIMAB AS SINGLE AGENT IN PATIENTS WITH MULTIPLE MYELOMA |
| https://doi.org/10.1093/annonc/mdx262.011 | Impact of prior bevacizumab treatment on VEGFA and PlGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial |
| https://doi.org/10.1080/00015385.2020.1820683 | Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy |
| https://doi.org/10.1016/j.jaci.2020.12.149 | Children With Atopic Dermatitis (AD) Have a High Burden of Atopic Comorbidities: Results From a Large Worldwide Survey |
| https://doi.org/10.4155/bio-2021-0137 | Cloud Solutions for GxP Laboratories: Considerations for Data Storage |